Dr. Pecora on the CPIT001 Study in Hematologic Malignancies
Andrew L. Pecora, MD
Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the CPIT001 study for patients with hematologic malignancies.
The CPIT001 trial is investigating the safety and efficacy of the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplant in patients with high-risk hematologic malignancies. The first 29 patients enrolled experienced adverse events but those were not unexpected, says Percora.